MESO — Mesoblast Limited

Summary of Mesoblast Q2 2026 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenues: $51.3 million for the first half of FY 2026, driven primarily by the launch of Ryoncil.
• Net Product Revenues: $49 million from Ryoncil, with a gross margin of 93%.
• R&D Expenses: Increased to $46.2 million from $5.1 million in the prior year, reflecting investments in clinical trials and manufacturing.
• SG&A Expenses: Rose to $28.5 million from $18 million, largely due to sales and marketing efforts.
• Net Loss: Reduced to $40.2 million from $48 million year-over-year.
• Cash Position: $130 million as of December 31, 2025, bolstered by a $125 million nondilutive credit line.

2. Strategic Updates and Business Highlights:

• Ryoncil Launch: Successful rollout with significant market adoption; targeting 20% market share by the end of FY 2026.
• Treatment Centers: 49 centers onboarded, with 30 included on formularies, facilitating broader access.
• Insurance Coverage: Ryoncil is covered by plans representing over 280 million lives, with Medicaid coverage in all states.
• Label Expansion: Initiating studies for Ryoncil in adult acute graft versus host disease (GVHD) due to promising preliminary results.
• Pipeline Development: Focus on second-generation products like rexlemestrocel-L for chronic low back pain and chronic heart failure, with ongoing trials and a BLA filing anticipated.

3. Forward Guidance and Outlook:

• Revenue Projections: Full-year net revenues for Ryoncil expected to range between $110 million and $120 million.
• Clinical Trials: Continued focus on expanding indications for Ryoncil and advancing the pipeline for chronic pain and heart failure therapies.

4. Bad News, Challenges, or Points of Concern:

• Increased Expenses: Significant rise in R&D and SG&A expenses may pressure profitability in the short term.
• Market Penetration Risks: Achieving the targeted 20% market share in pediatrics may be challenging, depending on physician education and adoption rates.
• FDA Approval Uncertainties: While there is optimism regarding BLA filings, the evolving regulatory landscape and requirements could pose risks.

5. Notable Q&A Insights:

• Market Penetration Assumptions: Management clarified that the 20% penetration target is based on a dynamic patient population estimate and is aimed for the end of FY 2026.
• FDA Discussions: Confidence in receiving full approval for Revascor based on constructive discussions with the FDA regarding mortality endpoints and the sufficiency of a single well-conducted trial for approval.
• Chronic Back Pain Submission: The ongoing Phase III trial will serve as the primary data set for the BLA, with completion expected by mid-2026.

Overall, Mesoblast demonstrated strong initial performance with Ryoncil, backed by strategic initiatives and a solid financial position, while also facing challenges related to expense management and regulatory approvals.